[Case Study] Akari Shigemi “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance” (AMR Alliance Japan, December 22, 2021)
date : 12/22/2021
Tags: AMR
As part of the Alliance’s project to promote antimicrobial steward among medical professionals, AMR Alliance Japan (Secretariat: Health and Global Policy Institute (HGPI)) has begun publishing case studies from various experts related to antimicrobial resistance.
Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital) reports a case titled “The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”.
Case study 04
Dr. Akari Shigemi (Division of Pharmacy / Department of Infection Control and Prevention, Kagoshima University Hospital)
“The importance of proper antimicrobial use for MRSA infections – Beware of rifampicin monotherapy induced resistance”
For further information, please see the case study below.
Case study 01
Dr. Keiji Okinaka (Director of Infection Control and Prevention Section, National Cancer Center Hospital East / Department of General Internal Medicine, National Cancer Center Hospital East /Division of Hematopoietic Stem Cell Transplantation, National Cancer Center Hospital)
“A disseminated filamentous fungal infection that broke through echinocandin antifungal treatment”
Top Research & Recommendations Posts
- [Policy Recommendations] Joint Statement “Protecting the Health of Both the Planet and People — A Japan-Model Planetary Health Strategy to Turn the Climate Crisis into an Opportunity for Health, the Economy, and Growth” (June 24, 2026)
- [Research Report] Energy Conservation and Greenhouse Gas Emissions Reduction in Healthcare Facilities: Case Studies from New Construction and Facility Renewal (March 16, 2026)
- [Recommendations] Strengthening Epidemiology Education in the Veterinary Field for the One Health Era (June 19, 2026)
- [Activity Report] HGPI Contributed to the Development of the Civil 7 (C7) Global Health Working Group’s Climate and Health Thematic Brief for the G7 (June 25, 2026)
- [Research Report] AMR Policy Update #6: The New Global Action Plan on AMR (Part 1)
- [Policy Recommendations] Developing a National Health and Climate Strategy for Japan (June 26, 2024)
- [Research Report] Perceptions, Knowledge, Actions and Perspectives of Healthcare Organizations in Japan in Relation to Climate Change and Health: A Cross-Sectional Study (November 13, 2025)
- [Research Report] AMR Policy Update #8: Fostering AMR-Conscious Youth: The Antibiotic Smart Sweden Certificate Program and its Implications for Early Childhood Education (July 1, 2026)
- [Research Report] AMR Policy Update #7: The New Global Action Plan on AMR (Part 2)
- [Announcement] HGPI Joins the UHC2030 Task Force for the 2027 UN High-Level Meeting on UHC (July 6, 2026)
Featured Posts
-
2026-06-04
[Registration Open] (Webinar) The 3rd J-PEP Seminar “Social Participation of People with Intractable Diseases and the Potential of a New Way of Working — ‘RD Workers’ — Lessons from Policy Advocacy Practice” (July 22, 2026)
-
2026-06-19
[Recommendations] Strengthening Epidemiology Education in the Veterinary Field for the One Health Era (June 19, 2026)
-
2026-07-02
[Research Report] Medical Practitioner Interviews on the Current State and Issues for Interdepartmental Collaboration in Clinical Practice for Chronic Kidney Disease (June 30, 2026)
-
2026-07-21
[Announcement] Announcement of the 2nd Kiyoshi Kurokawa Award Recipient



